Dopamine Receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of dopamine receptors. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4 receptors are members of the D2-like family.
Dopamine Receptor Inhibitors & Modulators

(±)-Methotrimeprazine (D6) (dl-Methotrimeprazine D6) Cat. No.: HY-19489S

Bioactivity: (±)-Methotrimeprazine (D6) is the deuterium labeled Methotrimeprazine, which is a D3 dopamine and Histamine H1 receptor antagonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

5-HT6/7 antagonist 1 Cat. No.: HY-101622

Bioactivity: 5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

A-437203 (Lu201640; A37203) Cat. No.: HY-U00185

Bioactivity: A-437203 is a selective D3 receptor antagonist with Kd of 71, 1.6, and 6220 nM for D2, D3, and D4 receptors, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Abaperidone Cat. No.: HY-101619

Bioactivity: Abaperidone is a potent antagonist of 5-HT2A receptor and dopamine D2 receptor with IC50s of 6.2 and 17 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

ABT-670 Cat. No.: HY-19483

Bioactivity: ABT-670 is a selective, oral bioavailable agonist of dopamine D4 receptor, with EC50 of 89 nM, 160 nM, and 93 nM for humanD4, ferretD4, and ratD4, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Adoprazine (SLV313) Cat. No.: HY-14782

Bioactivity: Adoprazine, a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.

Purity: 98.13%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Alizapride hydrochloride Cat. No.: HY-A0125A

Bioactivity: Alizapride hydrochloride is a dopamine receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg

Amisulpride (DAN 2163) Cat. No.: HY-14545

Bioactivity: Amisulpride is a dopamine D2/D3 receptor antagonist with Kd of 2.8 and 3.2 nM for human dopamine D2 and D3, respectively.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg

Amisulpride hydrochloride (DAN 2163 hydrochloride) Cat. No.: HY-14545A

Bioactivity: Amisulpride hydrochloride is a dopamine D2/D3 receptor antagonist with Kd of 2.8 and 3.2 nM for human dopamine D2 and D3, respectively.

Purity: >98%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Amifitadine hydrochloride (DOV-21947 hydrochloride; EB-1010 hydrochloride) Cat. No.: HY-18332A

Bioactivity: Amifitadine hydrochloride is a triple reuptake inhibitor (TRI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Ki values for SERT/NET/ DAT are 99/262/213 nM. The IC50 values for serotonin, norepinephrine and dopamine reuptake are 12/23/96 nM.

Purity: >98%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apomorphine hydrochloride hemihydrate</td>
<td>HY-12723A</td>
<td>Apomorphine hydrochloride hemihydrate is a non-selective dopamine agonist which activates both D1-like and D2-like receptors, with some preference for the latter subtypes.</td>
<td>99.94%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td>Azaperone</td>
<td>HY-B1470</td>
<td>Azaperone acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridylpiperazine and butyrophenone neuroleptic drug with sedative and antemetic effects, which is used mainly as a tranquilizer in veterinary medicine.</td>
<td>99.84%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td>B-HT 920</td>
<td>HY-A0008</td>
<td>B-HT 920(Talipexole 2Hcl) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays anti-Parkinsonian activity</td>
<td>99.99%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Benzamide Derivative 1</td>
<td>HY-U00415</td>
<td>Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>Blonanserin</td>
<td>HY-13575</td>
<td>Blonanserin(AD-5423) is a D2/5-HT2 receptor antagonist, atypical antipsychotic</td>
<td>99.92%</td>
<td>Launched</td>
<td>10 mg, 25 mg, 100 mg</td>
</tr>
<tr>
<td>Brexpiprazole</td>
<td>HY-15780</td>
<td>Brexpiprazole is a potent partial agonist at human 5-hydroxytryptamine (5-HT) 5-HT1A (K_i=0.12 nM) and dopamine D2L (K_i=0.3 nM) receptors, and an antagonist at 5-HT2A receptors (K_i=0.47 nM).</td>
<td>99.38%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</td>
</tr>
<tr>
<td>Bromocriptine mesylate</td>
<td>HY-12705A</td>
<td>Bromocriptine mesylate is a potent dopamine D2/D3 receptor agonist, which binds D2 dopamine receptor with pK_i of 8.05±0.2.</td>
<td>99.79%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg</td>
</tr>
<tr>
<td>Bromopride</td>
<td>HY-B1164</td>
<td>Bromopride is a dopamine antagonist with prokinetic properties widely used as an antiemetic.</td>
<td>&gt;98%</td>
<td>Launched</td>
<td>5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Cabergoline</td>
<td>HY-15296</td>
<td>Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D_2, D_3, and 5-HT_2B receptors (K_i=0.7, 1.5, and 1.2, respectively).</td>
<td>99.47%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Cariprazine</td>
<td>HY-14763</td>
<td>Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM).</td>
<td>98.01%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>
Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Bioactivity: Cariprazine hydrochloride is a novel antipsychotic drug candidate that exhibits high affinity for the D_3 (K_i=0.085 nM) and D_2 (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM)....

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: CGP 25454A is a novel and selective presynaptic dopamine autoreceptor antagonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg
Dexpramipexole (R)-Pramipexole; R-(-)-Pramipexole; KNS-760704)  
**Cat. No.: HY-17355B**

**Bioactivity:** Dexpramipexole (KNS-760704), also known as R-(-)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist. IC50 Value:

**Purity:** >98%

**Clinical Data:** Phase 3

**Size:** 10 mg, 50 mg

---

Dexpramipexole dihydrochloride ((R)-Pramipexole dihydrochloride; KNS 760704; SND 919CL2X)  
**Cat. No.: HY-17355A**

**Bioactivity:** Dexpramipexole 2HCl (KNS-760704), also known as R-(-)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist.

**Purity:** 98.01%

**Clinical Data:** Phase 3

**Size:** 10 mM x 1 mL in DMSO, 10 mg, 50 mg

---

Domperidone (R33812)  
**Cat. No.: HY-80411**

**Bioactivity:** Domperidone is a dopamine blocker and an antidopaminergic reagent.

**Purity:** 99.52%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 100 mg, 200 mg, 500 mg

---

Dopamine hydrochloride (ASL279)  
**Cat. No.: HY-80451A**

**Bioactivity:** Dopamine HCl is a catecholamine neurotransmitter present in a wide variety of animals. And a dopamine D1-5 receptors agonist.

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 100 mg, 500 mg

---

Dopamine serotonin antagonist-1  
**Cat. No.: HY-42110**

**Bioactivity:** Dopamine serotonin antagonist-1 is a dual dopamine and serotonin receptor antagonist with Ki of 200, 2500, 420, 39, 84, 40 nM for dopamine D1, D2, D4, and serotonin S2A, S2C, S3, respectively.

**Purity:** 99.00%

**Clinical Data:** No Development Reported

**Size:** 10 mM x 1 mL in DMSO, 10 mg, 50 mg, 100 mg

---

Droperidol (Dehydrobenzperidol)  
**Cat. No.: HY-B1240**

**Bioactivity:** Droperidol is a Dopamine-2 Receptor Antagonist.

**Purity:** 99.29%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 100 mg

---

Fenoldopam (SKF 82526)  
**Cat. No.: HY-80735**

**Bioactivity:** Fenoldopam (SKF 82526) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 10 mg

---

Fenoldopam mesylate (Fenoldopam methanesulfonate; SKF-82526 mesylate)  
**Cat. No.: HY-80735A**

**Bioactivity:** Fenoldopam (SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.

**Purity:** 99.85%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 10 mg, 50 mg, 100 mg

---

Fluphenazine dihydrochloride  
**Cat. No.: HY-A0081**

**Bioactivity:** Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.

**Purity:** 99.96%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 100 mg

---

GSK163090  
**Cat. No.: HY-14348**

**Bioactivity:** GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.

**Purity:** >98%

**Clinical Data:** Phase 2

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
### Haloperidol

**Cat. No.: HY-14538**

**Bioactivity:** Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

**Purity:** 99.72%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

---

### Haloperidol D4

**Cat. No.: HY-14538S**

**Bioactivity:** Haloperidol D4 is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

### Haloperidol D4‘

**Cat. No.: HY-14538S1**

**Bioactivity:** Haloperidol D4‘ is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg

---

### Haloperidol hydrochloride

**Cat. No.: HY-14538A**

**Bioactivity:** Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 100 mg, 500 mg

---

### Iloperidone (HP 873)

**Cat. No.: HY-17410**

**Bioactivity:** Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.

**Purity:** 99.33%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

---

### Iloperidone hydrochloride (HP 873 hydrochloride)

**Cat. No.: HY-17410A**

**Bioactivity:** Iloperidone (hydrochloride) is a D(2)/5-HT(2) receptor antagonist, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 10 mg, 50 mg, 100 mg

---

### L-DOPA (Levodopa; 3,4-Dihydroxyphenylalanine)

**Cat. No.: HY-N0304**

**Bioactivity:** L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease

**Purity:** 99.72%

**Clinical Data:** Launched

**Size:** 200 mg, 1 g

---

### Levosulpiride (S(-)-Sulpiride)

**Cat. No.: HY-B1059**

**Bioactivity:** Levosulpiride is the (S)-enantiomer of sulpiride, which is a D2 receptor antagonist, an atypical antipsychotic drug of the benzamide class.

**Purity:** 99.99%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg

---

### Lumateperone Tosylate (ITI-007)

**Cat. No.: HY-19733**

**Bioactivity:** Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM).

**Purity:** 99.21%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

### Lurasidone

**Cat. No.: HY-B0032A**

**Bioactivity:** Lurasidone is an antagonist of both dopamine D2 and 5-HT7 receptors with IC50 of 1.68 and 0.495 nM, respectively. Lurasidone is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th><strong>Lurasidone Hydrochloride</strong> (SM-13496)</th>
<th>Cat. No.: HY-B0032</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Lurasidone is an antagonist of both dopamine $D_2$ and $5-HT_7$, with $IC_{50}$ of 1.68 and 0.495 nM, respectively. Lurasidone is also a partial agonist of $5-HT_{1A}$ receptor with an $IC_{50}$ of 6.75 nM.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.85%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Launched</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Metoclopramide</strong></th>
<th>Cat. No.: HY-17382</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Metoclopramide is a dopamine D2 antagonist that is used as an antiemetic.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 98.23%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Metoclopramide hydrochloride hydrate</strong> (Metoclopramide monohydrochloride monohydrate)</th>
<th>Cat. No.: HY-17382A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Metoclopramide hydrochloride hydrate is a dopamine D2 antagonist that is used as an antiemetic.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.94%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM x 1 mL in DMSO, 100 mg, 500 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NEO 376</strong></th>
<th>Cat. No.: HY-101583</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> NEO 376 is a selective modulator of $5-HT_1$ receptor, GABA receptor and dopamine receptor, with anti-psychotic activity.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Molindone hydrochloride</strong> (EN-1733A)</th>
<th>Cat. No.: HY-B1017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.2%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM x 1 mL in DMSO, 10 mg, 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NEU 376</strong></th>
<th>Cat. No.: HY-101583</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> NEO 376 is a selective modulator of $5-HT_1$ receptor, GABA receptor and dopamine receptor, with anti-psychotic activity.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nomifensine</strong> ((±)-Nomifensin)</th>
<th>Cat. No.: HY-B1110</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Nomifensine is a norepinephrine-dopamine reuptake inhibitor, increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.24%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM x 1 mL in DMSO, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nomifensine maleate</strong> ((±)-Nomifensine maleate)</th>
<th>Cat. No.: HY-B1110A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Nomifensine maleate is a selective inhibitor of dopamine uptake, used in adult attention deficit disorder</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.14%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM x 1 mL in DMSO, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NRA-0160</strong></th>
<th>Cat. No.: HY-101641</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> NRA-0160 is a selective dopamine D4 receptor antagonist, with a $K_i$ value of 0.48 nM and with negligible affinity for dopamine D2 receptor ($K_i \geq 10000$ nM), D3 receptor ($K_i \geq 39$ nM), rat 5-HT2A receptor ($K_i \geq 180$ nM) and ra...</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg, 10 mg, 20 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Nuciferine</strong></th>
<th>Cat. No.: HY-N0049</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Nuciferine is an antagonist at $5-HT_{2A}$ ($IC_{50}=478$ nM), $5-HT_{2C}$ ($IC_{50}=131$ nM), and $5-HT_{2B}$ ($IC_{50}=1$ μM), an inverse agonist at $5-HT_{2A}$ ($IC_{50}=150$ nM), a partial agonist at $D_2$</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.66%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg</td>
<td></td>
</tr>
</tbody>
</table>
Ocaperidone (R79598)  
**Cat. No.:** HY-101094

**Bioactivity:** Ocaperidone is an effective antipsychotic agent, acting as a potent 5-HT₂ and dopamine D₂ antagonist, and a 5-HT₁A agonist, with a Kᵦ₅ of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT₂, 5-HT₁A, and dopamine receptors.

**Purity:** 98.55%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

Oxidopamine hydrobromide (6-Hydroxydopamine hydrobromide; 6-OHDA)  
**Cat. No.:** HY-B1081A

**Bioactivity:** Oxidopamine hydrobromide is a selective catecholaminergic neurotoxin, depletes brain catecholamine levels via uptake and accumulation by a transport mechanism specific to these neurons.

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

---

Paliperidone (9-hydroxyrisperidone)  
**Cat. No.:** HY-A0019

**Bioactivity:** Paliperidone (9-hydroxyrisperidone) is a dopamine antagonist of the atypical antipsychotic class of medications.

**Purity:** 99.09%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg

---

Pardoprunox (SLV-308; DU-126891)  
**Cat. No.:** HY-14958

**Bioactivity:** Pardoprunox (SLV-308) is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist; D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%); also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8...)

**Purity:** >98%

**Clinical Data:** Phase 3

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

Paliperidone hydrobromide (6-Hydroxydopamine hydrobromide; 6-OHDA)  
**Cat. No.:** HY-B1081

**Bioactivity:** Oxidopamine hydrochloride is a neurotoxic synthetic organic compound, selectively destroys dopaminergic and noradrenergic neurons in the brain.

**Purity:** 99.50%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg

---

Pergolide mesylate (Pergolide methanesulfonate; LY127809)  
**Cat. No.:** HY-13720A

**Bioactivity:** Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

**Purity:** 99.31%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

---

Perphenazine  
**Cat. No.:** HY-100143

**Bioactivity:** Perphenazine is a novel dopamine release inhibitor.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

Org-10490  
**Cat. No.:** HY-U00077

**Bioactivity:** Org-10490 is an antagonist of dopamine D1 receptor and dopamine D2 receptor, used for the treatment of psychiatric disease.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

Pentiapine (CGS 10746)  
**Cat. No.:** HY-100143

**Bioactivity:** Pentiapine is a novel dopamine release inhibitor.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

Perphenazine  
**Cat. No.:** HY-A0077

**Bioactivity:** Perphenazine is a typical antipsychotic drug, inhibits 5-HT2A receptor (5-HT2A), Alpha-1A adrenergic receptor (α1A), Dopamine receptor D2/D3, D2L receptor, and Histamine H1 receptor (H1) with Kᵦ₅ of 5.6, 10, 0.765/0.13, 3.4, and 8 nM.

**Purity:** 99.93%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 1 g, 5 g
<table>
<thead>
<tr>
<th>Compounds</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Perphenazine D8 Dihydrochloride</strong></td>
<td>HY-A0077AS</td>
<td>Perphenazine D8 Dihydrochloride is the deuterium labeled Perphenazine, which is a typical antipsychotic drug(5-HT, Dopamine receptor ligand).</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td><strong>PF-592379</strong></td>
<td>HY-U00400</td>
<td>PF-592379 is a potent dopamine D₃ receptor agonist with an EC₅₀ of 21 nM.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td><strong>Pimozide</strong> (R6238)</td>
<td>HY-12987</td>
<td>Pimozide is a dopamine receptor antagonist, with Kᵢ of 1.4 nM, 2.5 nM and 588 nM for dopamine D₂, D₃ and D₁ receptors, respectively, and also has affinity at α₁-adrenoceptor, with a Kᵢ of 39 nM; Pimozide also inhibits STAT3 and STAT5.</td>
<td>98.01%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 50 mg</td>
</tr>
<tr>
<td><strong>Piperidine-MO-1</strong></td>
<td>HY-19845A</td>
<td>Piperidine-MO-1 is a modulator of dopamine receptor extracted from patent WO/2005/121087A1, compound example 2; exhibits an ED₅₀ of 68 μmol/kg on increase of DOPAC in the rat striatum.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td><strong>Piribedil</strong></td>
<td>HY-12707</td>
<td>Piribedil is a dopamine D₂ receptor (D₂R) agonist which also displays antagonist property at α₁a-adrenoceptor (α₁a-AR).</td>
<td>99.90%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</td>
</tr>
<tr>
<td><strong>Piribedil D8</strong> (ET-495 D₈)</td>
<td>HY-12707S</td>
<td>Piribedil D8 is the deuterium labeled Piribedil, which is an antiparkinsonian agent.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td><strong>Pramipexole</strong></td>
<td>HY-B0410</td>
<td>Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).</td>
<td>&gt;98%</td>
<td>Launched</td>
<td>50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>Pramipexole dihydrochloride</strong></td>
<td>HY-17355</td>
<td>Pramipexole dihydrochloride</td>
<td>98.0%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg</td>
</tr>
<tr>
<td><strong>Pridopidine</strong> (ACR16; ASP2314; FR310826)</td>
<td>HY-10684</td>
<td>Pridopidine acts as a low affinity dopamine D₂ receptor (D₂R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S₁R) with Kᵢ, between 70 and 80 nM, which is ~100× higher than its affinity toward D₂R.</td>
<td>99.76%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>Prochlorperazine D₈</strong></td>
<td>HY-80807S</td>
<td>Prochlorperazine D₈ is the deuterium labeled Prochlorperazine, which is a dopamine (D₂) receptor antagonist.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
</tbody>
</table>
Prochlorperazine D8 dimeleate  
**Cat. No.: HY-B0807S1**

**Bioactivity:** Prochlorperazine D8 dimeleate is the deuterium labeled Prochlorperazine, which is a dopamine (D2) receptor antagonist.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg

Promazine hydrochloride  
**Cat. No.: HY-B1225**

**Bioactivity:** Promazine (hydrochloride) is a D2 dopamine receptor antagonist, belongs to the phenothiazine class of antipsychotics, used to treat schizophrenia.

**Purity:** 99.88%
**Clinical Data:** Launched
**Size:** 10mM x 1mL in Water, 100 mg

Quetiapine D4 fumarate  
**Cat. No.: HY-B00315**

**Bioactivity:** Quetiapine D4 fumarate is the deuterium labeled Quetiapine, which is an atypical antipsychotic.

**Purity:** 98.0%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

Quetiapine fumarate  
**Cat. No.: HY-B0031**

**Bioactivity:** Quetiapine fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.

**Purity:** 99.54%
**Clinical Data:** Launched
**Size:** 10mM x 1mL in DMSO, 1 g, 5 g

Quetiapine sulfoxide dihydrochloride  
**Cat. No.: HY-G0014A**

**Bioactivity:** Quetiapine Sulfoxide is a metabolite of Quetiapine. Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder.

**Purity:** 98.0%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 50 mg

Quinagolide hydrochloride  
**Cat. No.: HY-13736A**

**Bioactivity:** Quinagolide hydrochloride is a selective dopamine D2 receptor agonist, also is a prolactin inhibitor

**Purity:** 99.78%
**Clinical Data:** Launched
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

rac-Rotigotine Hydrochloride  
**Cat. No.: HY-15394**

**Bioactivity:** rac-Rotigotine Hcl is a high potency and selectivity agonist for D-2 receptor with Ki of 0.69 nM.

**Purity:** 97.76%
**Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

Risperidone  
**Cat. No.: HY-11018**

**Bioactivity:** Risperidone(R 64 766) is a serotonin 5-HT2 receptor blocker(Ki= 0

**Purity:** 99.16%
**Clinical Data:** Launched
**Size:** 10 mg, 50 mg, 100 mg

Risperidone hydrochloride  
**Cat. No.: HY-11018A**

**Bioactivity:** Risperidone Hcl(R 64 766 Hcl) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM).

**Purity:** >98%
**Clinical Data:** Launched
**Size:** 10 mg, 50 mg, 100 mg

Risperidone mesylate  
**Cat. No.: HY-11018B**

**Bioactivity:** Risperidone mesylate(R 64 766 mesylate) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM).

**Purity:** >98%
**Clinical Data:** Launched
**Size:** 10 mg, 50 mg, 100 mg
**Ro 10-5824 dihydrochloride**

**Bioactivity:** Ro 10-5824 dihydrochloride is a selective dopamine D4 receptor partial agonist, with $K_i$ of 5.2 nM.

**Purity:** 98.89%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg

---

**Ropinirole hydrochloride**

**Bioactivity:** Ropinirole hydrochloride (SKF 101468 hydrochloride) is a selective dopamine D2 receptor inhibitor with IC50 of 29 nM.

**Purity:** 99.93%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg

---

**Rotigotine**

**Bioactivity:** Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with $K_i$s of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

**Purity:** 99.98%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

---

**Rotigotine Hydrochloride**

**Bioactivity:** Rotigotine Hydrochloride is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with $K_i$s of 0.71nM, 4-15nM, and 83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

**Purity:** 99.99%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg

---

**Rotigotine D7 Hydrochloride**

**Bioactivity:** Rotigotine D7 Hydrochloride is the deuterium labeled Rotigotine(N-0923), which is a dopamine D2 and D3 receptor agonist.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

SB-277011

**Bioactivity:** SB-277011 is a potent and selective dopamine D3 receptor antagonist ($pK_i$ values are 8.0, 6.0, 5.0 and <5.2 for D3, D2, 5-HT1D and 5-HT1B respectively); brain penetrant.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 10 mg, 50 mg

---

**Rotundine**

**Bioactivity:** Rotundine is an antagonist of dopamine D1, D2 and D3 receptors with IC$_{50}$s of 166 nM, 1.4 μM and 3.3 μM, respectively. Rotundine is also an antagonist of 5-HT$_1A$, with an IC$_{50}$ of 370 nM.

**Purity:** 99.88%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 50 mg

---

**Rotundine**

**Bioactivity:** Rotundine is an antagonist of dopamine D1, D2 and D3 receptors with IC$_{50}$s of 166 nM, 1.4 μM and 3.3 μM, respectively. Rotundine is also an antagonist of 5-HT$_1A$, with an IC$_{50}$ of 370 nM.

**Purity:** 99.88%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

**SCH 23390 hydrochloride**

**Bioactivity:** SCH 23390 hydrochloride is a potent dopamine receptor D1 antagonist with $K_i$ values of 0.2 and 0.3 nM for the D1 and D5.

**Purity:** 99.31%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Sertindole**

**Bioactivity:** Sertindole, a neuroleptic, is one of the newer antipsychotic medications available

**Purity:** 96.14%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg
**SKF 38393 hydrochloride**  
((±)-SKF-38393 hydrochloride; SKF-38393)  
Cat. No.: HY-12520A

**Bioactivity:** SKF 38393 hydrochloride is a D1 agonist with IC50 of 110 nM.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg

---

**SKF 82958**  
((±)-SKF 82958; Chloro-AP)  
Cat. No.: HY-10435

**Bioactivity:** SKF 82958 is a D1/D5 receptor full agonist.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**SKF-82958 hydrobromide**  
((±)-SKF 82958 hydrobromide; Chloro-APB hydrobromid)  
Cat. No.: HY-10435A

**Bioactivity:** SKF 82958 hydrobromide is a D1/D5 receptor full agonist.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 25 mg, 50 mg

---

**ST-836 hydrochloride**  
Cat. No.: HY-15238

**Bioactivity:** ST-836 Hcl is a dopamine receptor ligand; Antiparkinsonian agent.

**Purity:** 99.95%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**ST-836**  
Cat. No.: HY-15238

**Bioactivity:** ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 25 mg, 50 mg

---

**Sulpiride**  
Cat. No.: HY-B1019

**Bioactivity:** Sulpiride is a D2 receptor antagonist, an atypical antipsychotic drug of the benzamide class, used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.

**Purity:** 99.99%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 100 mg

---

**Sultopride**  
Cat. No.: HY-42849

**Bioactivity:** Sultopride is a selective antagonist of dopamine D2 receptor.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 25 mg, 50 mg

---

**Sultopride hydrochloride**  
Cat. No.: HY-42849A

**Bioactivity:** Sultopride hydrochloride is a selective antagonist of dopamine D2 receptor.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

---

**Sumanirole maleate**  
(U95666E; PNU 95666; PNU 95666E; Sumanirole)  
Cat. No.: HY-70081A

**Bioactivity:** Sumanirole maleate(PNU 95666E; U95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM

**Purity:** 98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 25 mg, 50 mg, 100 mg

---

**Talipexole**  
(B-HT 920; B-HT920)  
Cat. No.: HY-A0040

**Bioactivity:** Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent.

**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg
Bioactivity: Tetrahydroberberine is an isoquinoline alkaloid isolated from corydalis tuber; has micromolar affinity for dopamine D(2) (pK(i) = 6.28) and 5-HT(1A) (pK(i) = 5.38) receptors but moderate to no affinity for other relevant serotonin receptors (5-HT(1B), 5-HT(1D), 5-HT(3), and 5-HT(4); pK(i) < 5.00).
Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL in DMSO, 5 mg, 10 mg

Bioactivity: Tetrahydropalmatine, an active component isolated from corydalis, acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats.
Purity: >99.07%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL in DMSO, 10 mg, 50 mg

Bioactivity: Thioridazine is an antipsychotic drug, used in the treatment of schizophrenia and psychosis, shows D4 selectivity or serotonin antagonism.
Purity: 99.93%
Clinical Data: Phase 4
Size: 10 mM x 1 mL in DMSO, 100 mg, 500 mg

Bioactivity: Tiapride hydrochloride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome.
Purity: >98%
Clinical Data: Launched
Size: 100 mg

Bioactivity: Trifluoperazine dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic.
Purity: 99.0%
Clinical Data: Launched
Size: 10 mM x 1 mL in DMSO, 100 mg, 500 mg

Bioactivity: Triflupromazine hydrochloride is an antipsychotic medication, which are Dopamine D1/D2 receptor antagonists.
Purity: 99.96%
Clinical Data: Launched
Size: 10 mM x 1 mL in DMSO, 100 mg

Bioactivity: Trimethobenzamide hydrochloride is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic to prevent nausea and vomiting.
Purity: 99.70%
Clinical Data: Launched
Size: 10 mM x 1 mL in DMSO, 100 mg, 200 mg, 500 mg

Bioactivity: U91356 is a dopamine receptor agonist.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Bioactivity: Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Bioactivity: Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.
Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg
**Ziprasidone D8**  
(CP-88059 D8)  
Cat. No.: HY-14542S

**Bioactivity:** Ziprasidone D8 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

**Purity:** > 98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

---

**Ziprasidone hydrochloride**  
(CP-88059 hydrochloride)  
Cat. No.: HY-14542A

**Bioactivity:** Ziprasidone HCl(CP-88059 HCl) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

**Purity:** > 98%  
**Clinical Data:** Launched  
**Size:** 10 mg, 50 mg

---

**Ziprasidone hydrochloride monohydrate**  
(CP 88059)  
Cat. No.: HY-17407

**Bioactivity:** Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.

**Purity:** 98.29%  
**Clinical Data:** Launched  
**Size:** 10 mM x 1 mL in DMSO, 10 mg, 50 mg